Skip to main content
SpringerLink
Log in

Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

An Erratum to this article was published on 05 September 2017

This article has been updated

Abstract

Background and Objectives

Although the use of oral risperidone in children and adolescents has been well studied, there is little information on the intramuscular use of long-acting injectable risperidone (LAIR). The aims of this study were to investigate the effectiveness and adverse effects of LAIR in children and adolescents with conduct disorder, bipolar disorder, and schizophrenia.

Methods

In total, 42 patients (age range 12–17 years) who were non-adherent to oral antipsychotic drugs, received 25 mg of LAIR intramuscularly every 2 weeks. The drug was administered at least four times and up to 66 times (median drug use: 9.50 times). The effectiveness and adverse effects of the treatment were examined.

Results

There was an improvement in 13 (92.8%) of the 14 patients diagnosed with bipolar disorder, in 25 (78.1%) of 32 patients diagnosed with conduct disorder and in one (50%) of two patients diagnosed with schizophrenia. Six patients had comorbid conduct disorder and bipolar disorder. Totally, 81% of the patients improved with LAIR. Weight-gain, daytime somnolence, muscle stiffness and spasms, impaired concentration, and fatigue were the most common side effects through the whole sample. Menstrual problems were common in girls. In the study, 57.1% of the patients continued to receive their injections regularly until the end of the treatment, under physician control. A total of 16.7% discontinued the treatment due to non-adherence. The LAIR treatment was terminated in 26.2% of the patients, due to weight-gain, dystonia, and galactorrhea.

Conclusions

In children and adolescents with conduct disorder, bipolar disorder and schizophrenia who show noncompliance with oral drugs, LAIR may improve treatment compliance. LAIR is a reliable treatment in terms of its effectiveness. Weight-gain, dystonia, and galactorrhea were the adverse effects that were responsible for LAIR treatment cessation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 05 September 2017

    An erratum to this article has been published.

References

  1. Scahill L, Oesterheld JR, Martin A. General principles, specific drug treatments, and clinical practice. In: Martin A, Volkmar FR, editors. Lewis’ child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 754–88.

    Google Scholar 

  2. Schatzberg AF, Nemeroff CB. The American psychiatric publishing textbook of psychopharmacology. 4th ed. Washington DC: American Psychiatric Pub; 2009.

    Google Scholar 

  3. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.

    Article  CAS  PubMed  Google Scholar 

  4. Rainer MK. Risperidone long-acting injection: a review of its long-term safety and efficacy. Neuropsychiatr Dis Treat. 2008;4:919–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed T, et al. Double-blind randomized trial of risperidone vs. divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12:593–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord. 2004;1:103–11.

    Article  Google Scholar 

  7. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:634–41.

    Article  Google Scholar 

  8. Gorman DA, Gardner DM, Murphy AL, Feldman M, Bélanger SA, Steele MM, Boylan K, Cochrane-Brink K, Goldade R, Soper PR, Ustina J, Pringsheim T. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60:62–76.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rickards H, Cavanna AE, Worrall R. Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol. 2012;16:361–4.

    Article  PubMed  Google Scholar 

  10. Fu-I L, Boarati MA, Stravogiannis A, Wang YP. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry. 2009;70(4):604–6.

    Article  PubMed  Google Scholar 

  11. Pope S, Zaraa SG. Efficacy of long-acting injectable antipsychotics in adolescents. J Child Adolesc Psychopharmacol. 2016;26:391–4.

    Article  CAS  PubMed  Google Scholar 

  12. Boarati MA, Wang YP, Ferreira-Maia AP, Cavalcanti AR, Fu-I L. Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder. Prim Care Companion CNS Disord. 2013;15:3.

    Google Scholar 

  13. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–8.

    Article  CAS  PubMed  Google Scholar 

  14. Wechsler D. WISC-R manual for the wechsler intelligence scale for children-revised. New York: Psychological Corporation; 1974.

    Google Scholar 

  15. Kaufman AS, Lichtenberger E. Assessing adolescent and adult intelligence. 3rd ed. Hoboken: Wiley; 2006.

    Google Scholar 

  16. Gokler B, Unal F, Pehlivanturk B, Kultur EC, Akdemir D, Taner Y. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version—the validity and reliability of adaptation in Turkish. Çocukve Gençlik Ruh Saglıgı Dergisi. 2004;11:109–16.

    Google Scholar 

  17. Savaşır I, Şahin N. Wechsler CocuklarİcinZekaOlceği (WISCR) El Kitabı. Ankara: Turk PsikologlarDerneğiYayınları; 1995.

    Google Scholar 

  18. Guy W: Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76–338. National Institute of Mental Health, Rockville, MD. 1976; 218–222.

  19. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650–3.

    Article  CAS  PubMed  Google Scholar 

  20. Yilmaz S, Buzlu S. Liverpool Üniversitesi Antipsikotiklerin Yan Etkilerini Değerlendirme Ölçeği’nin Türkçe Formunun Güvenilirliği. Klinik Psikofarmakoloji Bülteni. 2006;16(3):147–54.

    Google Scholar 

  21. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Risperidone conduct study group: effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026–36.

    Article  PubMed  Google Scholar 

  22. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509–16.

    Article  CAS  PubMed  Google Scholar 

  23. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van DS. Risperidone disruptive behavior study group. Risperidone in children with disruptive behavior disorders and sub-average intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2005;44:64–72.

    Article  PubMed  Google Scholar 

  24. Rey JM, Walter G, Soutullo CA. Oppositional defiant and conduct disorders. In: Martin A, Volkmar FR, editors. Lewis’ child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 454–66.

    Google Scholar 

  25. Blader JS, Jensen PS. Aggression in children: an integrative approach. In: Martin A, Volkmar FR, editors. Lewis’ child and adolescent psychiatry: a comprehensive textbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 467–83.

    Google Scholar 

  26. Wu CS, Hsieh MH, Tang CH, Chang CJ. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. J Affect Disord. 2016;197:189–95.

    Article  CAS  PubMed  Google Scholar 

  27. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:e9290.

    Article  Google Scholar 

  28. Chue P, Llorca P, Duchesne I, Leal A, Rosillon D, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res. 2005;5:266–74.

    CAS  Google Scholar 

  29. Beauclair L, Chue P, McCormic J, Camacho F, Lam A, Luong D. Impact of risperidone long-acting injectable on hospitalization and medication use in Canadian patients with schizophrenia. J Med Econ. 2007;10:427–42.

    Article  Google Scholar 

  30. Fusar-Poli P, Kempton MJ, Rosenheck RA. Effcacy and safetyof second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28:57–66.

    Article  PubMed  Google Scholar 

  31. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr. 2007;12:21–6.

    Article  PubMed  Google Scholar 

  32. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br. J. Psychiatr. 2004;184:509–16.

    Article  Google Scholar 

  33. Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-actingInjectable antipsychotics post-hospital discharge. J Clin Psychopharmacol. 2015;35(4):442–6.

    CAS  PubMed  Google Scholar 

  34. Lambert T, Emmerson B, Hustig H, Resseler S, Jacobs A, Butcher B. e-STAR Research Group. Long-acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry. 2012;26:12–25.

    Google Scholar 

  35. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69:26–36.

    Article  CAS  PubMed  Google Scholar 

  36. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600–20.

    Article  CAS  PubMed  Google Scholar 

  37. Morselli PL, Pippenger CE. Drug disposition during development: an overview. In: Fundamentals. Applied Therapeutic Drug Monitoring. Vol 1. 2nd edition. The American Association for Clinical Chemistry, Washington DC. 1982; 63–70.

  38. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125–32.

    Article  PubMed  Google Scholar 

  39. Kent JM, Hough D, Singh J, Karcher K, Pandina G. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2013;23:676–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical antipsychotic trials of intervention effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.

    Article  CAS  PubMed  Google Scholar 

  41. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32:309–16.

    Article  CAS  PubMed  Google Scholar 

  42. Lostia AM, Mazzarini L, Pacchiarotti I, Lionetto L, De Rossi P, Sanna L, Sani G, Kotzalidis GD, Girardi P, Simmaco M, Tatarelli R. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit. 2009;31:475–81.

    Article  CAS  PubMed  Google Scholar 

  43. Musenga A, Saracino MA, Sani G, Raggi MA. Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. Curr Med Chem. 2009;16:1463–81.

    Article  CAS  PubMed  Google Scholar 

  44. Spina E, Hiemke C, de Leon J. Assessing drug -drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the adolescent patients and their families who participated in the study.

Author information

Authors and Affiliations

  1. Child and Adolescent Psychiatry Department, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey

    Mehmet Fatih Ceylan, Betül Erdogan & Selma Tural Hesapcioglu

  2. Child and Adolescent Psychiatry Department, Ankara Pediatric and Pediatric Hematology Oncology Training and Research Hospital, Ankara, Turkey

    Esra Cop

Authors
  1. Mehmet Fatih Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Betül Erdogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selma Tural Hesapcioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Esra Cop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Fatih Ceylan.

Ethics declarations

Funding

This study was not supported by any pharmaceutical company.

Conflict of interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

The study was approved by Ankara Yildirim Beyazit University Yenimahalle Education and Research Hospital Ethics Board. All procedures performed were in accordance with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Written informed consent was obtained from all individual participants and their families included in the study.

Additional information

The text under the methods section was incorrectly published in the original publication. The correct value is now updated in the original article.

An erratum to this article is available at https://doi.org/10.1007/s40261-017-0567-3.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ceylan, M.F., Erdogan, B., Tural Hesapcioglu, S. et al. Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. Clin Drug Investig 37, 947–956 (2017). https://doi.org/10.1007/s40261-017-0555-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-017-0555-7

Search

Navigation